Company: GIFLF
Filing Date: 2025-02-26
Form Type: 6-K
Source: 0001104659-25-017501
Chunk: 28

Company: Grifols SA
Filing Date: 2025-02-26
Form: 6-K
Chunk 28
---
reciation & Amortization (439) (443) (444) (441) (458) Reported EBITDA 1,631 1,518 1,450 1,375 1,239 Leverage Ratio Reported 5.6x 6.1x 6.5x 8.0x 8.5x

- 38 - Q4 2024 Results NCI Contributions In thousand of euros GDS Biotest BPC Haema Profit after tax from continuing operations 124,205 (96,194) 27,720 6,191 Income tax expense (40,798) (9,624) (6,692) (13,882) Financial result 71,486 (33,890) (953) 7,312 Amortisation and depreciation (47,132) (54,779) (7,963) (8,630) Consolidated EBITDA 140,649 2,100 43,328 21,391 Impact IFRS16- Finance Leases (leases of plasma donation centre properties) (2,403) (8,183) (5,564) (4,663) Restructuring costs 3,315 1,050 - 230 Share of profits assoc core activit 2024 - 4,388 - - Impairment - 15,304 - - Consolidated EBITDA under Credit Agreement 141,561 14,658 37,763 16,958 % of non-controlling interest 45.00% 29.82% 100.0% 100.0% Consolidated EBITDA according to Credit Agreement non-controlling interest 63,702 4,371 37,763 16,958 Cash and cash equivalents (561) (107,849) (11,300) (20,983) Financial assets/liabilities with Grifols (1,107,461) 536,447 - - Leasing liabilities (leases of real estate of plasma donation centres) 13,308 58,565 59,475 12,848 Loans and other financial liabilities 11,928 74,532 18 - Total Balance Sheet Net Debt (1,082,787) 561,694 48,192 (8,135) Impact IFRS16- Finance Leases (leases of plasma donation centre properties) (13,308) (58,565) (59,